Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
Kathryn C. Arbour(Memorial Sloan Kettering Cancer Center), Matthew D. Hellmann(Memorial Sloan Kettering Cancer Center)
Cited by 67
Related Papers
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
|Clinical Cancer Research|2021|108